StockData
Bicycle Therapeutics PLC logo

Bicycle Therapeutics PLC (BCYC) stock

BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 11/3080% below fair value
$3.18−0.19 (-5.64%)

Close on Nov 16, 2026Market cap $222.90MP/E –Yield 0.00%

Bicycle Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Bicycle Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $175.25M, down 26.5% year over year. For fiscal 2025 it was $240.28M, up 38.9% from the year before. The highest annual figure on record is $240.28M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$240.28M+38.9%
FY2024Dec 31, 2024$172.97M+10.5%
FY2023Dec 31, 2023$156.50M+91.8%
FY2022Dec 31, 2022$81.61M+81.8%
FY2021Dec 31, 2021$44.88M+35.4%
FY2020Dec 31, 2020$33.15M+29.8%
FY2019Dec 31, 2019$25.54M+23.0%
FY2018Dec 31, 2018$20.76M+75.0%
FY2017Dec 31, 2017$11.87M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$33.42M-42.8%
Q2 FY2026Jun 30, 2026$41.16M-42.1%
Q1 FY2026Mar 31, 2026$48.90M-17.2%
Q4 FY2025Dec 31, 2025$51.77M+4.0%
Q3 FY2025Sep 30, 2025$58.43M+21.1%
Q2 FY2025Jun 30, 2025$71.03M+77.3%
Q1 FY2025Mar 31, 2025$59.06M+69.4%
Q4 FY2024Dec 31, 2024$49.78M+11.4%
Q3 FY2024Sep 30, 2024$48.27M+21.1%
Q2 FY2024Jun 30, 2024$40.06M+0.9%
Q1 FY2024Mar 31, 2024$34.86M+8.2%
Q4 FY2023Dec 31, 2023$44.70M+80.8%
Q3 FY2023Sep 30, 2023$39.87M+75.2%
Q2 FY2023Jun 30, 2023$39.72M+100.1%
Q1 FY2023Mar 31, 2023$32.21M+125.5%
Q4 FY2022Dec 31, 2022$24.72M+90.8%
Q3 FY2022Sep 30, 2022$22.75M+116.4%
Q2 FY2022Jun 30, 2022$19.85M+69.4%
Q1 FY2022Mar 31, 2022$14.28M+47.4%
Q4 FY2021Dec 31, 2021$12.96M+28.8%
Q3 FY2021Sep 30, 2021$10.51M+42.8%
Q2 FY2021Jun 30, 2021$11.72M+47.3%
Q1 FY2021Mar 31, 2021$9.69M+24.7%
Q4 FY2020Dec 31, 2020$10.06M+51.3%
Q3 FY2020Sep 30, 2020$7.36M+21.1%
Q2 FY2020Jun 30, 2020$7.96M+21.7%
Q1 FY2020Mar 31, 2020$7.77M+23.9%
Q4 FY2019Dec 31, 2019$6.65M+2.4%
Q3 FY2019Sep 30, 2019$6.08M+7.7%
Q2 FY2019Jun 30, 2019$6.54M+32.9%
Q1 FY2019Mar 31, 2019$6.28M–
Q4 FY2018Dec 31, 2018$6.49M–
Q3 FY2018Sep 30, 2018$5.64M–
Q2 FY2018Jun 30, 2018$4.92M–

More Bicycle Therapeutics figures

See a number that looks wrong?